The global healthcare industry is undergoing a significant transformation as molecular diagnostics continue to reshape infectious disease detection and management. According to MarketsandMarkets, the global Molecular Infectious Disease Testing Market is projected to grow from USD 11.30 billion in 2026 to USD 19.09 billion by 2031, registering a robust CAGR of 11.1% during the forecast period.
The report, titled “Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) – Global Forecast to 2031,” highlights the growing importance of molecular diagnostics in modern healthcare systems.
As infectious diseases continue to evolve globally, healthcare providers, diagnostic laboratories, and public health agencies are increasingly relying on advanced molecular testing technologies for rapid, accurate, and reliable disease detection.
Rising Burden of Infectious Diseases Driving Market Expansion
One of the primary factors fueling market growth is the increasing prevalence of infectious diseases worldwide. Conditions such as HIV, hepatitis, influenza, gastrointestinal infections, sexually transmitted diseases (STDs), and hospital-acquired infections (HAIs) continue to pose major healthcare challenges.
In recent years, emerging infectious diseases and global outbreaks have further emphasized the importance of rapid and precise diagnostic solutions. Traditional diagnostic techniques often require longer turnaround times and may lack the sensitivity needed for early detection. Molecular infectious disease testing addresses these limitations by enabling highly accurate pathogen identification at the genetic level.
The growing focus on early diagnosis, disease surveillance, outbreak prevention, and personalized treatment strategies is significantly increasing the adoption of molecular testing technologies across healthcare facilities worldwide.
Technological Advancements Accelerating Market Growth
Continuous innovations in molecular diagnostics are playing a vital role in advancing the market. Significant investments in research and development have led to the introduction of highly efficient and automated testing platforms that improve accuracy, reduce turnaround time, and support high-throughput testing.
Technologies such as polymerase chain reaction (PCR), multiplex testing, next-generation sequencing (NGS), and isothermal nucleic acid amplification are transforming infectious disease diagnostics. These technologies enable healthcare professionals to detect multiple pathogens simultaneously while improving diagnostic sensitivity and specificity.
Automation and digital integration are also enhancing laboratory workflows, reducing manual errors, and improving operational efficiency. The growing demand for decentralized testing and point-of-care diagnostics is expected to further stimulate innovation in this market over the coming years.
PCR Technology Continues to Dominate the Market
By technology, the PCR segment accounted for the largest share of the molecular infectious disease testing market in 2025. PCR remains the gold standard in molecular diagnostics due to its exceptional sensitivity, accuracy, and reliability in detecting pathogens.
PCR technology has become widely accepted because it allows clinicians and laboratory professionals to identify infectious agents quickly and accurately, even in samples containing very low pathogen concentrations. The availability of optimized testing protocols, high-quality reagents, and advanced commercial kits has further strengthened the adoption of PCR-based diagnostics.
In addition, automation advancements in PCR platforms have simplified laboratory workflows and improved testing efficiency. Automated PCR systems enable high-throughput testing, making them particularly valuable during infectious disease outbreaks and large-scale screening programs.
The continued demand for rapid and accurate diagnostic solutions is expected to sustain the strong position of PCR technology in the global market throughout the forecast period.
Multiplex Testing Gaining Significant Attention
Multiplex molecular testing is emerging as one of the most promising areas within infectious disease diagnostics. Unlike singleplex testing, multiplex assays can detect multiple pathogens simultaneously using a single sample.
This capability is particularly beneficial in respiratory infections, gastrointestinal diseases, and sexually transmitted infections, where symptoms often overlap among different pathogens. Multiplex testing helps clinicians make faster and more informed treatment decisions while reducing the need for multiple individual tests.
The increasing demand for cost-effective and time-efficient diagnostic solutions is expected to accelerate the adoption of multiplex molecular assays across hospitals and diagnostic laboratories worldwide.
Diagnostic Laboratories Emerging as the Fastest-Growing End User
Based on end users, diagnostic laboratories are projected to be the fastest-growing segment in the molecular infectious disease testing market.
The growing burden of infectious diseases, combined with rising awareness regarding early diagnosis and disease monitoring, has significantly increased the demand for advanced diagnostic services. Diagnostic laboratories are increasingly adopting molecular testing technologies such as PCR, multiplex assays, and NGS to improve testing capabilities and deliver rapid results.
These laboratories benefit from advanced infrastructure, skilled professionals, and the ability to handle large testing volumes efficiently. During public health emergencies and outbreaks, diagnostic laboratories play a critical role in disease surveillance and large-scale testing initiatives.
Moreover, increasing investments in laboratory automation and molecular testing infrastructure are expected to further support the growth of this segment over the next few years.
North America Leads the Global Market
Geographically, North America accounted for the largest share of the molecular infectious disease testing market in 2025.
The region’s dominance can be attributed to several factors, including advanced healthcare infrastructure, strong adoption of innovative diagnostic technologies, and well-established reimbursement systems. North America also benefits from robust infectious disease surveillance programs and effective outbreak management strategies.
The presence of leading biotechnology and diagnostic companies, coupled with substantial investments in healthcare innovation and research activities, has strengthened the region’s leadership position in the market.
Furthermore, favorable regulatory frameworks and increased public awareness regarding early disease detection continue to support market expansion across the United States and Canada.
Competitive Landscape
The molecular infectious disease testing market is highly competitive, with several global players focusing on technological innovation, product development, strategic collaborations, and geographic expansion.
Some of the major companies operating in the market include Danaher, Hologic, Inc., Abbott, Thermo Fisher Scientific Inc., QIAGEN, Revvity, Becton, Dickinson and Company, and QuidelOrtho Corporation.
These companies are actively investing in advanced molecular platforms, expanding their infectious disease testing portfolios, and strengthening their global market presence.
Future Outlook
The future of the molecular infectious disease testing market appears highly promising. Growing concerns regarding emerging infectious diseases, increasing demand for rapid diagnostics, and ongoing technological advancements are expected to continue driving market growth.
As healthcare systems increasingly prioritize early detection, precision diagnostics, and efficient disease management, molecular testing technologies will become even more essential in clinical practice. Innovations in PCR, NGS, multiplex diagnostics, and point-of-care testing are likely to further improve accessibility, affordability, and diagnostic performance.
With strong industry investments and expanding healthcare infrastructure worldwide, the molecular infectious disease testing market is set to play a critical role in shaping the future of global infectious disease management through 2031.
